PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead Sciences has | Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was ...

Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...

Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.